Browsing by Author "Chiong, Mario"
Now showing 1 - 20 of 40
Results Per Page
Sort Options
- ItemÁcido úrico: una molécula con acciones paradójicas en la insuficiencia cardiaca(2011) Alcaíno, Hernán; Greig, Douglas; Castro Gálvez, Pablo Federico; Verdejo Pinochet, Hugo; Mellado Suazo, Rosemarie; García, Lorena; Díaz Araya, Guillermo; Quiroga Lagos, Clara Rosa; Chiong, Mario; Lavandero, Sergio
- ItemAcute effect of iloprost inhalation on right atrial function and ventricular dyssynchrony in patients with pulmonary artery hypertension(2017) Gabrielli, Luigi; Ocaranza, María Paz; Sitges, Marta; Kanacri, Andrés; Saavedra Madariaga, Rodrigo Alejandro; Sepúlveda, Pablo; Sepúlveda, Luis; Rossel, Víctor; Zagolin, Mónica; Verdejo Pinochet, Hugo; Baraona Reyes, Fernando Exequiel; Zalaquett Sepúlveda, Ricardo; Chiong, Mario; Lavandero, Sergio; Castro Gálvez, Pablo Federico
- ItemAngiotensin II-Regulated Autophagy Is Required for Vascular Smooth Muscle Cell Hypertrophy(2019) Mondaca-Ruff, David; Riquelme, Jaime A.; Quiroga Lagos, Clara Rosa; Norambuena-Soto, Ignacio; Sanhueza-Olivares, Fernanda; Villar-Fincheira, Paulina; Hernández-Díaz,Tomás; Cancino-Arenas, Nicole; San Martín, Alejandra; García, Lorena; Lavandero, Sergio; Chiong, Mario
- ItemAngiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension(2018) Gonzalez, Leticia; Novoa, Ulises; Moya, Jackeline; Gabrielli, Luigi; Jalil Milad, Jorge; Garcia, Lorena; Chiong, Mario; Lavandero, Sergio; Paz Ocaranza, Maria
- ItemAngiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro(LIPPINCOTT WILLIAMS & WILKINS, 2010) Paz Ocaranza, Maria; Lavandero, Sergio; Jalil, Jorge E.; Moya, Jaqueline; Pinto, Melissa; Novoa, Ulises; Apablaza, Felipe; Gonzalez, Leticia; Hernandez, Carol; Varas, Manuel; Lopez, Rene; Godoy, Ivan; Verdejo, Hugo; Chiong, MarioBackground Angiotensin-(1-9) is present in human and rat plasma and its circulating levels increased early after myocardial infarction or in animals treated with angiotensin-converting enzyme inhibitor. However, the cardiovascular effects of this peptide are unknown.
- ItemAutophagy and oxidative stress in non-communicable diseases: A matter of the inflammatory state?(2018) Pena-Oyarzun, Daniel; Bravo-Sagua, Roberto; Diaz-Vega, Alexis; Aleman, Larissa; Chiong, Mario; Garcia, Lorena; Bambs S., Claudia; Troncoso, Rodrigo; Cifuentes, Mariana; Morselli, Eugenia; Ferreccio Readi, Catterina; Quest, Andrew F. G.; Criollo, Alfred
- ItemBasal autophagy protects cardiomyocytes from doxorubicin-induced toxicity(2016) Pizarro, Marcela; Troncoso, Rodrigo; Martínez, Gonzalo; Chiong, Mario; Castro Gálvez, Pablo Federico
- Itembeta-Hydroxybutyrate Increases Exercise Capacity Associated with Changes in Mitochondrial Function in Skeletal Muscle(MDPI, 2020) Monsalves Alvarez, Matias; Morales, Pablo Esteban; Castro Sepulveda, Mauricio; Sepulveda, Carlos; Rodriguez, Juan Manuel; Chiong, Mario; Eisner, Veronica; Lavandero, Sergio; Troncoso, Rodrigobeta-hydroxybutyrate is the main ketone body generated by the liver under starvation. Under these conditions, it can sustain ATP levels by its oxidation in mitochondria. As mitochondria can modify its shape and function under different nutritional challenges, we study the chronic effects of beta-hydroxybutyrate supplementation on mitochondrial morphology and function, and its relation to exercise capacity. Male C57BL/6 mice were supplemented with beta-hydroxybutyrate mineral salt (3.2%) or control (CT, NaCl/KCl) for six weeks and submitted to a weekly exercise performance test. We found an increase in distance, maximal speed, and time to exhaustion at two weeks of supplementation. Fatty acid metabolism and OXPHOS subunit proteins declined at two weeks in soleus but not in tibialis anterior muscles. Oxygen consumption rate on permeabilized fibers indicated a decrease in the presence of pyruvate in the short-term treatment. Both the tibialis anterior and soleus showed decreased levels of Mitofusin 2, while electron microscopy assessment revealed a significant reduction in mitochondrial cristae shape in the tibialis anterior, while a reduction in the mitochondrial number was observed only in soleus. These results suggest that short, but not long-term, beta-hydroxybutyrate supplementation increases exercise capacity, associated with modifications in mitochondrial morphology and function in mouse skeletal muscle.
- ItemCirculating Vascular Cell Adhesion Molecule-1 (sVCAM-1) Is Associated With Left Atrial Remodeling in Long-Distance Runners(FRONTIERS MEDIA SA, 2021) Contreras Briceño, Felipe; Herrera, Sebastián; Vega Adauy, Julián; Salinas, Manuel; Ocaranza Jeraldino, María Paz; Jalil Milad, Jorge; Mandiola Ovalle, Jorge; García, Lorena; Chiong, Mario; Castro Galvez, Pablo Federico; Lavandero, Sergio; Gabrielli Nervi, Luigi ArnaldoIntroduction: An increased risk of atrial fibrillation (AF) has been demonstrated in high-performance athletes. Soluble vascular adhesion molecule-1 (sVCAM-1), a biomarker involved in inflammation and cardiac remodeling, is associated with the development of AF in the general population. However, the relationship between sVCAM-1 and left atrial (LA) remodeling has been poorly investigated in long-distance runners (LDR).Aim: To determine the association between LA remodeling and sVCAM-1 levels in LDR during the training period before a marathon race.Methods: Thirty-six healthy male LDR (37.0 +/- 5.3 years; 174.0 +/- 7.0 height; BMI: 23.8 +/- 2.8; V degrees O-2-peak: 56.5 +/- 7.3 mL center dot kg(-1)center dot min(-1)) were evaluated in this single-blind and cross-sectional study. The LDR were separated into two groups according to previous training levels: high-training (HT) (n = 18) >= 100 km center dot week(-1) and low-training (LT) (n = 18) >= 70 and <100 km center dot week(-1). Also, 18 healthy non-active subjects were included as a control group (CTR). In all participants, transthoracic echocardiography was performed. sVCAM-1 blood levels were measured baseline and immediately finished the marathon race in LDR.Results: HT showed increased basal levels of sVCAM-1 (651 +/- 350 vs. 440 +/- 98 ng center dot mL(-1) CTR, p = 0.002; and vs. 533 +/- 133 ng center dot mL(-1) LT; p = 0.003) and a post-marathon increase (Delta sVCAM-1) (651 +/- 350 to 905 +/- 373 ng center dot mL(-1); p = 0.002), that did not occur in LT (533 +/- 133 to 651 +/- 138 ng center dot mL(-1); p = 0.117). In LDR was a moderate correlation between LA volume and sVCAM-1 level (rho = 0.510; p = 0.001).Conclusions: In male long-distance runners, sVCAM-1 levels are directly associated with LA remodeling. Also, the training level is associated with basal sVCAM-1 levels and changes after an intense and prolonged exercise (42.2 km). Whether sVCAM-1 levels predict the risk of AF in runners remains to be established.
- ItemComposición farmacéutica que comprende angiotensina (1-9) o sus derivados, composición farmacéutica que comprende un vector que sobreexpresa la enzima convertidora de angiotensina-I homologa (ECA2), útil para prevenir, revertir, inhibir y/o dismunir el remodelado cardiovascular, pulmonar, renal y/o cerebralOcaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Alemania)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (España)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Francia)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Italia)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Reino Unido)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (USA)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemCounter-regulatory renin–angiotensin system in cardiovascular disease(2019) Ocaranza, María Paz; Riquelme, Jaime A.; García, Lorena; Jalil Milad, Jorge; Chiong, Mario; Santos, Robson A. S.; Lavandero, Sergio
- ItemEnergy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy(2012) Troncoso, Rodrigo; Vicencio, Jose Miguel; Parra, Valentina; Nemchenko, Andriy; Kawashima, Yuki; Del Campo, Andrea; Toro, Barbra; Battiprolu, Pavan K.; Aranguiz, Pablo; Chiong, Mario; Yakar, Shoshana; Gillette, Thomas G.; Hill, Joseph A.; Abel, Evan Dale; LeRoith, Derek; Lavandero, Sergio
- ItemFactor de crecimiento análogo a insulina-1 y cardiotrofina-1 inducido por ejercicio y su relación con hipertrofia miocárdica en maratonistas(2023) Chiong, Mario; Contreras Briceño, Felipe; Fernández, Rodrigo; Llevaneras, Silvana; Salinas, Manuel; Herrera, Sebastian; Saavedra, Rodrigo; Gabrielli, LuigiAntecedentes: El ejercicio de alta intensidad induce hipertrofia miocárdica necesaria para adaptar al corazón a la mayor demanda de trabajo. Se desconoce si correr una maratón induce de forma aguda factores humorales asociados al desarrollo de hipertrofia miocárdica en atletas. Objetivo: Evaluar cardiotrofina-1 (CT1) y el factor de crecimiento análogo a insulina-1 (IGF-1), conocidos inductores de hipertrofia, en maratonistas previo y justo después de correr una maratón y su relación con hipertrofia cardíaca. Métodos: Estudio prospectivo ciego simple de atletas hombres que corrieron la maratón de Santiago. Se incluyó un grupo control sedentario. En todos los sujetos se realizó un ecocardiograma transtorácico estándar. Los niveles de CT1 e IGF-1 se determinaron en plasma obtenidos antes (basal) y justo después de haber terminado (antes de 15 minutos) la maratón, usando test de ELISA. Resultados: Los atletas tenían frecuencias cardíacas menores que los controles, asociado con una mayor hipertrofia miocárdica, determinado por el grosor del septo y pared posterior del corazón, y volúmenes del ventrículo y aurícula izquierda. Los niveles basales de CT1 e IGF-1 fueron similares entre atletas y controles sedentarios. El correr la maratón aumentó los niveles de estas dos hormonas en un subgrupo de atletas. Solo los atletas que incrementaron los niveles de IGF-1, pero no de CT1, tenían volúmenes de ventrículo izquierdo y derecho más grandes que los otros atletas. Conclusiones: IGF-1 que se incrementa de forma aguda por el ejercicio, pero no CT1, estaría asociado con el aumento de los volúmenes ventriculares observado en los atletas.
- ItemGln(27)-> Glu beta(2)-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol(2009) Troncoso, Rodrigo; Moraga, Francisco; Chiong, Mario; Roldán Saelzer, Juan; Bravo, Roberto; Valenzuela Bassi, Rodrigo Andrés; Diaz-Araya, Guillermo; Del Campo, Andrea; Sanhueza, Carlos; Rodriguez, Andrea; Vukasovic, Jose Luis; Mellado Suazo, Rosemarie; Greig, Douglas; Castro Gálvez, Pablo Federico